Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

This study has been terminated.
(Closed due to insufficient recruitment)
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00234468
First received: October 5, 2005
Last updated: May 19, 2011
Last verified: May 2011

October 5, 2005
May 19, 2011
January 2004
Not Provided
Time to progression (2 years after Last patient in)
Same as current
Complete list of historical versions of study NCT00234468 on ClinicalTrials.gov Archive Site
  • Modalities of relapse or progression (2 years after Last patient in)
  • Overall survival (2 years after Last patient in)
Same as current
Not Provided
Not Provided
 
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (IressaTM) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy

The aim of the study if to determine if Iressa can prolong the period of time without any disease worsening (Time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or without radiotherapy or chemotherapy and radiotherapy

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Non Small Cell Lung Carcinoma
Drug: Iressa (Gefitinib)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
490
August 2007
Not Provided

Inclusion Criteria:

  • Histologically Confirmed Non Small Cell Lung Cancer.
  • Locally advanced disease previously treated with combined therapy (chemotherapy and surgery with or without radiotherapy, or chemotherapy and radiotherapy).
  • Chemotherapy with regimens containing cisplatin or carboplatin is mandatory
  • Response to combined therapy

Exclusion Criteria:

  • No previous treatment with ZD1839 or any other EGFR-targeted therapy
  • No progressive disease after combined therapy for locally advanced NSCLC
  • No presence of metastatic disease
  • No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
  • Any unresolved chronic toxicity from previous anticancer therapy.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
NCT00234468
1839IL/0126
Not Provided
Not Provided
AstraZeneca
Not Provided
Principal Investigator: Lucio Crino, MD Bologna Italy
AstraZeneca
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP